Kalo Gold (OTC:KLGDF) Stock, Quote.Headers.trade-ideas

Kalo Gold Corp is a mineral exploration company focused on the Vatu Aurum gold project on Fiji's north island, Vanua Levu. Geographic revenue is recognized in Canada, Fiji, British Virgin Islands.

Kalo Gold Corp

Fourth Quarter Fiscal 2024 Guidance
The company noted that it is reaffirming its fourth quarter fiscal 2024 guidance previously announced in conjunction with its third quarter fiscal 2024 financial results on August 8, 2024.
For reference, for the fiscal quarter ending September 30, 2024, the company expects revenue in the range of $44 million to $50 million; GAAP net loss in the range of ($32) million to ($28) million; and Adjusted EBITDA in the range of approximately ($19) million to ($13) million. The adjusted EBITDA guidance excludes acquisition-related costs, amortization of acquired intangible assets, stock-based compensation, restructuring and other costs. The GAAP net income guidance excludes potential goodwill impairment.
To learn more about Cerence, visit <a href="https://www.globenewswire.com/Tracker?data=5ih8DH5bwjWg7PpCwDzh_RKdBITxE2rU2IrrkW6irUDJcEIMUHxTeKnA-fJSb6ywdyz03cDYmdnCvDI-gv4iuQ==">www.cerence.com</a>, and follow the company on <a href="https://www.globenewswire.com/Tracker?data=QauV1OVQU2uN_bNe5L7vPWFiLxdr0LR2pWd2dFOrE5L2b9nQO9hZtIB3ccyHGQ9RP608Atx4TLfzWFkWv3CxttTmh_gS5_kyHazFwpxPmMk=">LinkedIn</a>.

News

Guidance

CRNC

UPDATE: Cerence Reaffirms Q4 Revenue Guidance Range Of $44M-$50M

Enhancing Loan Conversion And Fraud Prevention; New Integration Automates Income Verification, Instantly Detects 60%-80% Of Inflated Incomes, And Enables Up To 70% Application Decisioning Without Manual Intervention

LPRO

Open Lending Partners With Point Predictive To Integrate IEValidate And IncomePass Solutions

<a href="https://www.globenewswire.com/Tracker?data=vau5g4nONuS_f_2y7q9j2whf-d45WDHqZfQA2qBG34hNbPbf6bOQc2FifNAK403Og7GwLqmDJPDQ34wJdWtssA==">Cerence Inc.&nbsp;</a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNC#NASDAQ">CRNC</a>), AI for a world in motion, today announced that Brian Krzanich has been appointed Chief Executive Officer and a member of the Board of Directors, effective immediately. Mr. Krzanich succeeds Stefan Ortmanns, who is departing as CEO and resigning as a member of the Board.

Management

Cerence Appoints Brian Krzanich As Chief Executive Officer, Effective Immediately

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ncratleos.com%2F&amp;esheet=54131936&amp;newsitemid=20241007737332&amp;lan=en-US&amp;anchor=NCR+Atleos&amp;index=1&amp;md5=e1c3a516860fd6d0340107cf73b38422">NCR Atleos</a> Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NATL#NYSE">NATL</a>) ("Atleos"), a leader in expanding self-service financial access for financial institutions, retailers and consumers, today announced that $1.2 billion-asset <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cbtks.com%2F&amp;esheet=54131936&amp;newsitemid=20241007737332&amp;lan=en-US&amp;anchor=CoreFirst+Bank+%26amp%3B+Trust&amp;index=2&amp;md5=49a3e0a7e3f126439d6d9fa617223d0a">CoreFirst Bank &amp; Trust</a> has selected Atleos' <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ncratleos.com%2Fbanking%2Fatm-network-and-allpoint&amp;esheet=54131936&amp;newsitemid=20241007737332&amp;lan=en-US&amp;anchor=Allpoint+Network&amp;index=3&amp;md5=9a2b8e0b4abbe1c74a35d7ed43fe7ee4">Allpoint Network</a> to provide wider, more convenient access to everyday banking transactions for its customers.
Topeka, Kansas-based CoreFirst Bank &amp; Trust was looking for an efficient way to allow customers to conduct transactions at convenient retail locations in the communities CoreFirst serves today and across the United States. By joining Atleos' Allpoint Network, CoreFirst Bank &amp; Trust will quickly and easily provide surcharge-free access to over 40,000 ATMs in trusted retail locations across the country where customers already live and shop and accept cash deposits at more than 3,000 locations in the network including sites within Kansas.

NATL

CoreFirst Bank & Trust Has Selected Atleos' Allpoint Network To Provide Wider, More Convenient Access To Everyday Banking Transactions For Its Customers

Development Based On ModeX's MSTAR Technology To Prepare For Emerging Viral Threats

Biotech

General

ModeX Therapeutics Secures $35M BARDA Supplement For COVID Multispecific Antibodies And $16M For Influenza Program; Total BARDA Awards Now At $110M With Potential To Reach $205M If All Options Are Exercised

Transaction Reinforces AIR's Presence in Europe and Enhances its Capabilities for Integration of Advanced Robotics into Automated Systems
Vivian Farrell Promoted to President of Automated Industrial Robotics, Ireland
Automated Industrial Robotics Inc. ("AIR" or the "Company") today announced the acquisition of Robotics &amp; Drives ("RDS"), an Ireland-based industrial automation company focused on delivering innovative solutions through robotics technology. The transaction further reinforces AIR's presence in Europe, strengthens the Company's ability to integrate robotics solutions into its automated systems and adds to the product portfolio. The transaction was funded primarily by an additional investment from an Ares Management Private Equity fund ("Ares").

ARES

Automated Industrial Robotics Inc. Acquires Robotics & Drives; Terms Of The Transaction Were Not Disclosed

<h3>Gainers</h3>
<ul>
<li>Algorhythm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIME#NASDAQ">RIME</a>) shares rose 84.0% to $0.85 during Monday's pre-market session. The market value of their outstanding shares is at $8.2 million. </li>
<li>Jowell Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JWEL#NASDAQ">JWEL</a>) shares increased by 14.61% to $1.96. The market value of their outstanding shares is at $4.2 million. </li>
<li>Ambow Education Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AMBO#AMEX">AMBO</a>) stock moved upwards by 13.82% to $1.4. The company's market cap stands at $3.9 million. </li>
<li>QuantaSing Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) shares rose 11.82% to $4.16. The company's market cap stands at $212.6 million. </li>
<li>Vista Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSTO#NYSE">VSTO</a>) stock moved upwards by 10.19% to $43.9. The market value of their outstanding shares is at $2.5 billion. </li>
<li>Niu Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIU#NASDAQ">NIU</a>) shares moved upwards by 8.92% to $3.05. The market value of their outstanding shares is at $236.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Forza X1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRZA#NASDAQ">FRZA</a>) stock fell 16.2% to $0.28 during Monday's pre-market session. The company's market cap stands at $4.3 million. </li>
<li>Cheetah Net Supply Chain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNT#NASDAQ">CTNT</a>) stock fell 16.2% to $0.24. The company's market cap stands at $9.2 million. </li>
<li>Kaixin Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KXIN#NASDAQ">KXIN</a>) shares decreased by 8.83% to $0.32. The market value of their outstanding shares is at $18.7 million. </li>
<li>Phoenix Motor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEV#NASDAQ">PEV</a>) stock fell 7.6% to $0.99. The company's market cap stands at $34.6 million. As per the news, the Q1 earnings report came out 2 days ago. </li>
<li>Cango (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CANG#NYSE">CANG</a>) stock fell 6.49% to $1.73. The market value of their outstanding shares is at $180.5 million. </li>
<li>Betterware de Mexico SAPI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWMX#NYSE">BWMX</a>) stock decreased by 5.86% to $12.55. The market value of their outstanding shares is at $468.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AMBO

BWMX

CANG

CTNT

FRZA

JWEL

KXIN

RIME

VSTO

12 Consumer Discretionary Stocks Moving In Monday's Pre-Market Session

Consortium includes top universities, hospitals and industry partners, led by the Francis Crick Institute and The Royal Marsden NHS Foundation Trust &nbsp;
Akoya's platforms will be used for deep spatial proteomic profiling of thousands of tissue samples from cancer patients to identify biomarkers predicting treatment success
MARLBOROUGH, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=122HfIAZtGixbIM-qHTEm0omvPvTv7RaoKvm6oKLVoVLys4M9mvkmd-zY_dKY_ovCfvx4GEbXXl96uqvjy-rwtRNWO43vbvxlDZ3ef-ly0o=">Akoya Biosciences, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKYA#NASDAQ">AKYA</a>) ("Akoya"), The Spatial Biology Company&#xAE;, today announced that the company's PhenoCycler&#xAE;&nbsp;Fusion and PhenoImager&#xAE; HT spatial proteomics platforms will be used to analyze tissue samples as part of the MANIFEST (Multiomic Analysis of Immunotherapy Features Evidencing Success and Toxicity) program. This multimillion-dollar initiative, funded by the UK Office of Life Sciences (OLS) and the Medical Research Council (MRC), aims to advance cancer immunotherapy research through deep multi-omic profiling.
The MANIFEST consortium brings together leading cancer researchers, academic institutions, NHS trusts, and industry partners, to study why certain cancer patients respond to immunotherapy while others do not. Akoya's spatial biology platforms will play a pivotal role in profiling immune cell interactions within the tumor microenvironment, offering critical insights into biomarkers that may predict treatment outcomes and potential side effects.

AKYA

Akoya's Leading Spatial Proteomics Platforms Selected For Use By UK-Based MANIFEST Consortium To Revolutionize Cancer Immunotherapy

<h3>Gainers</h3>
<ul>
<li>Scholar Rock Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>) stock rose 198.1% to $22.12 during Monday's pre-market session. The company's market cap stands at $1.7 billion. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares increased by 53.16% to $0.17. The company's market cap stands at $2.0 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock increased by 15.21% to $0.31. The market value of their outstanding shares is at $2.2 million. </li>
<li>iBio (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#AMEX">IBIO</a>) stock moved upwards by 14.15% to $2.5. The market value of their outstanding shares is at $21.5 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock increased by 11.72% to $4.86. The market value of their outstanding shares is at $63.2 million. </li>
<li>Biohaven (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>) shares moved upwards by 10.58% to $52.67. The company's market cap stands at $5.3 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Trevena (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) shares fell 45.5% to $2.51 during Monday's pre-market session. The market value of their outstanding shares is at $2.1 million. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) shares fell 18.3% to $0.49. The company's market cap stands at $1.5 million. </li>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) stock declined by 14.69% to $4.01. The market value of their outstanding shares is at $2.9 million. </li>
<li>TriSalus Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSI#NASDAQ">TLSI</a>) shares decreased by 12.97% to $3.96. The company's market cap stands at $116.0 million. </li>
<li>SHL Telemedicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLT#NASDAQ">SHLT</a>) shares fell 12.61% to $2.98. The market value of their outstanding shares is at $48.8 million. </li>
<li>NKGen Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) stock decreased by 12.51% to $0.35. The market value of their outstanding shares is at $12.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BHVN

ENTO

IBIO

LGMK

NKGN

ONCO

SHLT

SRRK

TLSI

TRVN

12 Health Care Stocks Moving In Monday's Pre-Market Session

SRRK: 382% &#x7C; <a href="https://www.benzinga.com//node/41204463">Scholar Rock Holding shares are trading higher after the company announced topline results from the Phase 3 SAPPHIRE clinical trial evaluating the efficacy and safety of apitegromab in patients with SMA. The study achieved its primary endpoint.</a>
&nbsp;
ALTM: 47% &#x7C; <a href="https://www.benzinga.com//node/41204370">Arcadium Lithium shares are trading higher after the company announced that it has been approached by Rio Tinto regarding a potential acquisition.</a>
&nbsp;
TRVN: -55% &#x7C; <a href="https://www.benzinga.com//node/41204510">Trevena shares are trading lower after the company announced it received a Nasdaq delisting notification.</a>

Trading Ideas

ALTM

Market-Moving News for October 7th

<h3>Gainers</h3>
<ul>
<li>1847 Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#AMEX">EFSH</a>) stock rose 21.6% to $1.35 during Monday's pre-market session. </li>
<li>Surf Air Mobility (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NYSE">SRFM</a>) shares moved upwards by 16.49% to $2.26. The market value of their outstanding shares is at $28.9 million. </li>
<li>Mesa Air Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESA#NASDAQ">MESA</a>) shares moved upwards by 11.01% to $1.31. The market value of their outstanding shares is at $54.1 million. </li>
<li>Amprius Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPX#NYSE">AMPX</a>) stock rose 9.01% to $1.33. The market value of their outstanding shares is at $147.6 million. </li>
<li>EHang Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EH#NASDAQ">EH</a>) shares increased by 8.44% to $19.0. The company's market cap stands at $1.2 billion. </li>
<li>MingZhu Logistics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YGMZ#NASDAQ">YGMZ</a>) shares increased by 8.2% to $1.45. The market value of their outstanding shares is at $6.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Laser Photonics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASE#NASDAQ">LASE</a>) stock fell 49.6% to $3.56 during Monday's pre-market session. The market value of their outstanding shares is at $54.3 million. </li>
<li>Jayud Global Logistics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYD#NASDAQ">JYD</a>) shares decreased by 13.1% to $0.73. The company's market cap stands at $15.5 million. </li>
<li>noco-noco (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNC#NASDAQ">NCNC</a>) shares declined by 11.08% to $0.13. The market value of their outstanding shares is at $22.5 million. </li>
<li>American Rebel Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREB#NASDAQ">AREB</a>) stock decreased by 10.73% to $2.34. The company's market cap stands at $2.2 million. </li>
<li>Pineapple Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) shares fell 7.04% to $0.12. The market value of their outstanding shares is at $1.0 million. </li>
<li>Addentax Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXG#NASDAQ">ATXG</a>) shares declined by 7.02% to $0.76. The company's market cap stands at $4.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMPX

AREB

ATXG

EFSH

LASE

MESA

NCNC

PEGY

SRFM

YGMZ

12 Industrials Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Credo Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) stock moved upwards by 12.1% to $36.5 during Monday's pre-market session. The company's market cap stands at $6.0 billion. </li>
<li>Toyo Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOYO#NASDAQ">TOYO</a>) stock moved upwards by 11.55% to $2.8. The market value of their outstanding shares is at $124.1 million. </li>
<li>Wetouch Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WETH#NASDAQ">WETH</a>) shares rose 10.91% to $2.03. The company's market cap stands at $24.2 million. </li>
<li>OneConnect Financial Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OCFT#NYSE">OCFT</a>) shares rose 9.12% to $3.35. The company's market cap stands at $130.6 million. </li>
<li>ACM Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACMR#NASDAQ">ACMR</a>) stock rose 8.43% to $23.9. The market value of their outstanding shares is at $1.4 billion. </li>
<li>Aviat Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVNW#NASDAQ">AVNW</a>) shares moved upwards by 8.21% to $20.95. The company's market cap stands at $263.2 million. As per the press release, Q4 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>LeddarTech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LDTC#NASDAQ">LDTC</a>) shares decreased by 9.3% to $0.24 during Monday's pre-market session. The market value of their outstanding shares is at $7.2 million. </li>
<li>SPI Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPI#NASDAQ">SPI</a>) stock declined by 7.82% to $0.53. The market value of their outstanding shares is at $16.8 million. </li>
<li>Inseego (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSG#NASDAQ">INSG</a>) stock declined by 5.9% to $15.51. The company's market cap stands at $190.4 million. </li>
<li>Trident Digital Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDTH#NASDAQ">TDTH</a>) stock fell 4.62% to $3.1. The company's market cap stands at $200.0 million. </li>
<li>Ciena (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) shares fell 4.2% to $63.89. The company's market cap stands at $9.1 billion. </li>
<li>Sprinklr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXM#NYSE">CXM</a>) shares fell 3.76% to $7.18. The market value of their outstanding shares is at $1.9 billion. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACMR

AVNW

CIEN

CRDO

INSG

LDTC

OCFT

TDTH

TOYO

WETH

12 Information Technology Stocks Moving In Monday's Pre-Market Session

RARE

Ultragenyx Receives FDA Breakthrough Therapy Designation For Setrusumab (UX143) To Reduce Fracture Risk In Osteogenesis Imperfecta Types I, III, And IV For Patients Aged 2 And Older

Connexa Sports Technologies Inc. - Common Stock

YYAI

Yuanyu Enterprise Management Enters Exclusive License Agreement With Eternity Technology Limited; Eternity Agrees To License Yuanyu's Matchmaking Services For Love & Marriage Sector, Agreement Expected To Generate Over $19M In License Income Through End Of Dec. 2026

CELSIUS ESSENTIALS Watermelon Ice and Grape Slush Flavors to debut at NACS Show
MMA Fighter Dustin Poirier to host fan meet and greet at CELSIUS NACS booth N2939
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcelsiusholdingsinc.com%2F&amp;esheet=54131925&amp;newsitemid=20241007670736&amp;lan=en-US&amp;anchor=Celsius+Holdings%2C+Inc.&amp;index=1&amp;md5=59809776f26ab21dd4975ee61e595de4">Celsius Holdings, Inc.</a>, (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>), maker of CELSIUS, the premium lifestyle energy drink formulated to help individuals LIVE FIT&#x2122;, today announced the debut of two new flavors under its CELSIUS ESSENTIALS line at NACS Show 2024, including Watermelon Ice and Grape Slush. The 16-ounce CELSIUS ESSENTIALS line, which debuted last year at NACS Show, has grown to eight delicious, performance-focused flavors available at retailers across the United States.

CELH

CELSIUS Expands CELSIUS ESSENTIALS Line With Watermelon Ice And Grape Slush Flavors To Debut At NACS Show

Platform Enables Programmatic And Social Media Buying, Audience Activation, And Creative Personalization Using Real-Time Game And Fan Data; Features Include Fan-First Audiences, Premium Inventory, Bid Modeling, And Dynamic Creative Optimization For Tailored Marketing Strategies Across Multiple Channels

GENI

Genius Sports Launches FANHub, The World's First Omnichannel Advertising And Activation Platform To Engage Sports Fans

WIIM

NAPA

Duckhorn Portfolio shares are trading higher after the company reported better-than-expected Q4 financial results. Also, the company announced it into a definitive agreement to be acquired by private equity funds managed by Butterfly Equity.

Milestone moves program one step closer to operational testing
PORTSMOUTH, R.I., Oct. 7, 2024 /PRNewswire/ --&nbsp;Raytheon, an RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) business, recently conducted a series of controlled environmental tests for the Barracuda Mine Neutralization System at the Naval Surface Warfare Center Carderock Division.
Using a production representative test unit, Barracuda operated and collected data in environments of various sea states and water currents, demonstrating the ability to hydrodynamically control itself in conditions simulating the ocean.
The test demonstrated the ability of the vehicle to detect, track and hold position on a target on its own. It was the first time Raytheon has executed this type of testing with the Barracuda mine neutralizer underwater vehicle and moves the program one step closer towards meeting operational requirements.

RTX's Raytheon Completes Hydrodynamic Testing For The Barracuda Mine Neutralization System; Milestone Moves Program One Step Closer To Operational Testing

Dear Fellow Bionomics Shareholders,
This year continues to be a pivotal year for Bionomics, characterized by numerous wins and essential changes that have enhanced the Company and furthered our goal of creating therapies for the countless individuals suffering from anxiety and stress disorders.
As we enter the last quarter of 2024, I would like to take a moment to highlight a few of our recent accomplishments and milestones:
Strengthened the US-based management team and implemented necessary cost-cutting measures to ensure optimal runway for execution of our pipeline. Clinically, we advanced our lead program of BNC210 and initiated our first ever Phase 3 trial in social anxiety disorder (SAD) after successful regulatory interactions, expanded our IP portfolio through data-driven patent applications, extended BNC210's IP beyond 2040, and successfully communicated our scientific achievements in numerous banking, investor and scientific conferences. Financially, we secured funding though a private placement securities transaction and an ATM facility that allow us to complete our Phase 3 SAD study without compromising operational quality and speed of execution.
Additionally, we are in the final stages of redomiciling the Company to the U.S. and launching Neuphoria Inc, a company with new vision, strategy and CNS pipeline focus to fully leverage the strong U.S. biotechnology ecosystem, while maintaining our Australian presence and potential future tax benefits. During the ordinary course of this process, we plan to consolidate our issued shares of our trading securities and remain compliant with the NASDAQ Stock Market listing rules.
Thanks to these efforts, we believe the company is and will be fundamentally in a much stronger position today and moving forward.
As shareholders ourselves, we remain disappointed in Bionomics' stock performance, particularly following our Annual Report (10-K) filling on September 30, 2024. Yet, we believe that Bionomics is significantly undervalued, given our lead asset BNC210 is essentially a novel, "pipeline in a pill", small molecule with unique anxiolytic and antidepressant properties that can bring tremendous benefits to patients suffering from anxiety and stress disorders globally. Following the recent unfavorable industry developments with psychedelics in post-traumatic stress disorder (PTSD), unrelated to our product pipeline, Bionomics' BNC210 is the only promising registrational stage program with a novel mechanism of action having demonstrated the best clinical study outcomes in decades, (as announced in September 2023) with a clear path for an NDA submission, and with one successful registrational quality study already competed, requiring one additional successful Phase 3 trial for potential registration.
Of note, BNC210 also has two FDA fast track designations for SAD and PTSD programs, a sizable and favorable safety database supporting a differentiated non-sedating, non-addicting profile and positive datasets in four separate anxiety and stress-related indications. These clinical datasets and designations give us the ability to leverage regulatory privileges that can potentially accelerate review and approval. Moreover, we are also considering submitting a rebuttal in the future regarding the FDA decision to not grant a Breakthrough Designation in PTSD. It should also be noted that not being granted this designation does not in any way derail our progress or pathway in our clinical trials or intended operational success.
As we continue executing the Phase 3 program in SAD with anticipated readout in Q3 2025, we are also working diligently on exploring ways to enhance efficiencies and foster potential partnerships that will ensure our ability to drive the Phase 3 trial of BNC210 in PTSD to a successful NDA submission with a single trial. This would be a major achievement for the Company following our successful End-of-Phase 2 meeting with the FDA in June 2024. We have begun trial initiation activities, and we are on track to commence the Phase 3trial in PTSD in the second half of 2025 or sooner, contingent upon successful financing.
Our long-standing strategic partnership with MSD (known as Merck &amp; Co., Inc., Rahway NJ, USA in the U.S. and Canada) on the development of α7 receptor PAMs targeting cognitive dysfunction associated with Alzheimer's disease and other central nervous system conditions valued ~US $500M is quickly advancing and is anticipated to enter Phase 2 in the near future, triggering a sizable milestone payment for the Company.
Along with you, we believe Bionomics has significant, unrealized value that is not yet reflected in the current stock price.
We know from experience that transformations take time, and we strongly believe that we are on the right path and are excited for what lies ahead. We will continue to work industriously and prioritize prudent financial management, operational excellence and efficiency to further position Bionomics for future success and create shareholder value.
I would like to take this opportunity to thank you for your continued support and confidence in our Company.
If you have any questions or would like more information, please do not hesitate to contact us. Thank you for your continued partnership.
Sincerely,
Spyros Papapetropoulos M.D., Ph.D.
President &amp; CEO
Bionomics

BNOX

Bionomics CEO Issues Shareholder Letter Highlighting Recent Achievements And Strategic Vision; Emphasizes Executional Efficiencies And Outlook For Developing Novel CNS Therapies

Wearable Devices Ltd. (the "Company" or "Wearable Devices") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLDS#NASDAQ">WLDS</a>, WLDSW)))), a technology growth company specializing in artificial intelligence ("AI")-powered touchless sensing wearables, today announced that it intends to effect a one-for-twenty reverse split (the "Reverse Share Split") of the Company's ordinary shares, no par value per share (the "Ordinary Shares") and the Company's tradable warrants (the "Warrants"). The Ordinary Shares and Warrants will continue to trade on the Nasdaq Capital Market under the existing symbols "WLDS" and "WLDSW", respectively, and will begin trading on a split-adjusted basis when the market opens on October 10, 2024. The new CUSIP numbers for the Ordinary Shares and Warrants following the Reverse Share Split will be M97838 128 and M97838 151, respectively.
The Reverse Share Split was approved by the Company's shareholders at the Company's Annual and Special Meeting of Shareholders held on September 26, 2024, to be effected at the board of directors' discretion within approved parameters, and the board of directors has approved the 1-for-20 ratio. The Reverse Share Split will not result in an adjustment to the authorized share capital of the Company under the Company's amended and restated articles of association, as currently in effect (the "Articles"), which, as of the date hereof consists of 50,000,000 Ordinary Shares.

Stock Split

WLDS

Wearable Devices Ltd. Announces 1-For-20 Reverse Stock Split, Will Begin Trading On A Split-Adjusted Basis When The Market Opens On October 10, 2024

Kalo Gold announces C$1.5M non-brokered private placement

KLGDF

Kalo Gold

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Kalo Gold

Kalo Gold (KLGDF) Forecast

Kalo Gold (OTC:KLGDF) Stock, Quote.Headers.trade-ideas